Rankings
▼
Calendar
IMUX FY 2024 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena
IMUX
Immunic, Inc.
$135M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$98M
Net Income
-$101M
EPS (Diluted)
$-1.00
Cash Flow
Operating Cash Flow
-$85M
Free Cash Flow
-$85M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$41M
Total Liabilities
$22M
Stockholders' Equity
$18M
Cash & Equivalents
$36M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$98M
-$99M
+1.2%
Net Income
-$101M
-$94M
-7.4%
← Q4 2023
All Quarters
Q1 2024 →